Jiang Chen, Huang Li-Yun, Zhou Ji-Hao, Li Zhi-Ming, Wang Yu, Li Shuo, Fu Jian-Chang, Huang Qi-Tao, Yan Qin, Huang Yu-Yuan, Zuo Min, Hu Shimin, Gale Robert Peter, Liang Yang, Yun Jing-Ping, Huang Yu-Hua
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
iScience. 2023 Dec 18;27(1):108630. doi: 10.1016/j.isci.2023.108630. eCollection 2024 Jan 19.
The role of Epstein-Barr virus (EBV) in lymphoma cells of nodular sclerosis classic Hodgkin lymphoma (NScHL) is controversial. Our aim was to explore this and establish a clinically feasible model for risk stratification. We interrogated data from 542 consecutive subjects with NScHL receiving ABVD therapy and demonstrated EBV-infection in their lymphoma cells with EBV-encoded small RNAs (EBERs) hybridization. Subjects were divided into training and validation datasets. As data from the training dataset suggested EBERs-positivity was the only independent prognostic factor for both progression-free survival (PFS) and overall survival (OS), we developed corresponding prognostic models based on it. Our models showed excellent performance in both training and validation cohort. These data indicate the close association of EBV infection and the outcomes of persons with NScHL receiving ABVD. Additionally, our newly developed models should help physicians estimate prognosis and select individualized therapy.
爱泼斯坦-巴尔病毒（EBV）在结节硬化型经典霍奇金淋巴瘤（NScHL）淋巴瘤细胞中的作用存在争议。我们的目的是探讨这一问题，并建立一个临床可行的风险分层模型。我们分析了542例接受ABVD治疗的连续性NScHL患者的数据，并通过EBV编码的小RNA（EBERs）杂交在其淋巴瘤细胞中证实了EBV感染。将患者分为训练数据集和验证数据集。由于训练数据集的数据表明EBERs阳性是无进展生存期（PFS）和总生存期（OS）的唯一独立预后因素，我们据此开发了相应的预后模型。我们的模型在训练队列和验证队列中均表现出色。这些数据表明EBV感染与接受ABVD治疗的NScHL患者的预后密切相关。此外，我们新开发的模型应有助于医生评估预后并选择个体化治疗。
Zotero 插件
